Garetosmab
- Generic Name
- Garetosmab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2097125-54-5
- Unique Ingredient Identifier
- KR9ZSKO5QE
- Background
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of episodic, progressive heterotropic ossification. FOP is characterized by episodic inflammatory episodes, which may be precipitated by trauma, including immunizations and minor tissue damage, which usually result in ossification of the lesion. Patients experience abnormal car...
- Associated Conditions
- -
- Associated Therapies
- -
China's Laekna Joins Forces with Weight-Loss Giant Lilly on Muscle-Preserving Obesity
Eli Lilly and Laekna collaborate on an obesity drug, LAE102, targeting weight loss and muscle preservation. This move intensifies competition in the $150B obesity treatment market, dominated by Lilly and Novo Nordisk. Other companies like Regeneron and Scholar Rock are also developing muscle-preserving treatments, reflecting a growing focus on maintaining muscle mass during weight loss.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath